Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-25
SponsorSan Diego State University

About this trial

The study is a randomized, placebo-controlled design with the opioid antagonist, oral naltrexone. Following random assignment, participants will take 50mg of naltrexone or placebo once a day for 7 days. On days 1 - 7, participants complete reports of their feelings of social connection and mood in order to assess more naturalistic feelings in response to opportunities for social connection outside of the laboratory setting. Additionally, at the end of each day, they complete a physical symptoms questionnaire. On the 7th day, participants will come to the SDSU MRI scanning facility to complete tasks designed to elicit feelings of social connection in the fMRI scanner. After the scan, feelings in response to the scanner tasks will be collected.

Eligibility criteria

Qualifiers

good health

English fluency

willing to provide contact information for 4-6 close others

willing to provide digital photographs of 2 close others

Disqualifiers

presence of medical devices, implants, or other metal objects in or on the body that cannot be removed

tattooed eyeliner

a body habitus prohibiting MRI scanning

claustrophobia

Trial design

Treatments tested in this trial

  • Naltrexone Hydrochloride
  • Placebo

Treatment groups

210 Participants
are divided into 2 treatment groups

Sponsors and collaborators

San Diego State University

Lead sponsor

National Institute on Drug Abuse (NIDA)

Collaborator